Wockhardt Limited announced its first quarter results for FY 2026-27, reporting a significant 26% year-on-year revenue growth, reaching ₹929 crore. EBITDA also saw a robust increase of 86% to ₹188 crore. Profit After Tax (PAT) stood at ₹107 crore. The company highlighted strong performance across its business segments, including Novel Antibiotics, Biotechnology, and Pharmaceuticals.
Wockhardt Reports Strong Q1 FY27 Performance
Wockhardt Limited, a major player in the Pharmaceutical and Biotechnology sector, has released its financial results for the first quarter of the Financial Year 2026-27 (Q1 FY27). The company demonstrated robust growth across key financial metrics, signaling positive momentum.
Financial Highlights for Q1 FY27
During the quarter ended June 30, 2026, Wockhardt achieved a total revenue of ₹929 crore, marking a substantial increase of 26% compared to the previous year’s corresponding quarter (Q1 FY26), which stood at ₹738 crore. The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw an impressive growth of 86%, reaching ₹188 crore, up from ₹101 crore in Q1 FY26. Profit After Tax (PAT) for the quarter was reported at ₹107 crore, a significant improvement from a loss of ₹108 crore in the prior year’s quarter.
Performance Drivers and Segment Contributions
The company’s innovative portfolio, spanning Novel Antibiotics, Biotechnology, and Pharmaceuticals, contributed significantly to its performance. Notably, the innovative portfolio accounted for 27% of the revenue in Q1 FY27.
Key Financial Metrics (Q1 FY27 vs. Q1 FY26)
- Revenue: ₹929 Cr (+26%) vs ₹738 Cr
- EBITDA: ₹188 Cr (+86%) vs ₹101 Cr
- Profit Before Tax (PBT): ₹116 Cr vs ₹(97) Cr
- Profit After Tax (PAT): ₹107 Cr vs ₹(108) Cr
Biosimilar Segment Growth
The Biosimilar operations showed remarkable growth, contributing ₹236 crore and recording an increase of 112% compared to Q1 FY26. This surge was primarily driven by the Emerging Market biotech segment, which grew by approximately 146%.
Business and Product Updates
Wockhardt highlighted several key developments, including new product launches and approvals. The company filed 1 patent during the quarter and holds a total of 859 patents. The launch of products like EMROK O® and EMROK injection in Uganda, along with approvals for Zaynich® in the US and India, and progress on other novel antibiotics like Emrok®, Miqnaf®, and Foviscu®, underscore the company’s R&D and market expansion efforts.
The company’s strategic focus on addressing unmet medical needs, particularly in anti-bacterial drugs and diabetes care, continues to drive its business development and innovation pipeline.
Source: BSE
